David M. Goldstein
Direttore Tecnico/Scientifico/R&S presso PRINCIPIA BIOPHARMA INC.
Profilo
David M.
Goldstein is currently the Director at Frontier Medicines Corp., the Chief Scientific Officer at Principia Biopharma, Inc., and the Chief Scientific Officer at Alumis, Inc. Previously, he worked as the Senior Director-Medicinal Chemistry at Roche Holding AG from 1994 to 2011.
He also held a position as a Professor at Stanford University.
Dr. Goldstein obtained a doctorate degree from the University of Virginia and an undergraduate degree from Franklin & Marshall College.
Posizioni attive di David M. Goldstein
| Società | Posizione | Inizio |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2016 |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | 30/03/2021 |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | 01/09/2021 |
Precedenti posizioni note di David M. Goldstein
| Società | Posizione | Fine |
|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | 01/01/2011 |
| Stanford University | Corporate Officer/Principal | - |
Formazione di David M. Goldstein
| Franklin & Marshall College | Undergraduate Degree |
| University of Virginia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
 | Health Technology |
| Aziende private | 2 |
|---|---|
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Frontier Medicines Corp.
Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- David M. Goldstein
